RxDoctor Payments Data

Abdul Qadir, MD

Neurology · Warner Robins, GANPI 1992718100

Payments from drug & device makers

$2,764in general payments, 2019–2025

Across 134 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$598
  • Teva Pharmaceuticals USA, Inc.$421
  • AbbVie$254
  • Neurelis, Inc.$205
  • Supernus Pharmaceuticals, Inc.$181
  • Otsuka America Pharmaceutical, Inc.$141
  • plus $965 from 19 others

What the payments were for

  • Food & beverage$2,66897%
  • Education$963%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,764 in reported general payments places this provider in the 55th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$230,694
Medicare patients
765
Services billed
2,425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
QuliptaAtogepant48$70,016
UbrelvyUbrogepant14$49,770
AptiomEslicarbazepine Acetate26$35,972
Emgality PenGalcanezumab-Gnlm24$33,273
Aimovig AutoinjectorErenumab-Aooe15$31,422
VimpatLacosamide17$24,462
FycompaPerampanel19$23,797
KeppraLevetiracetam13$21,672
BriviactBrivaracetam11$21,516
Emgality SyringeGalcanezumab-Gnlm18$16,353
Oxcarbazepine86$16,078
Levetiracetam533$15,895
Lacosamide146$13,709
Divalproex Sodium80$5,805
Amitriptyline Hcl264$5,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$254$119,78562 claims
UCB, Inc.Vimpat, Briviact$598$45,97828 claims
Eisai Inc.Fycompa$34$23,79719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 506 neurology providers in Georgia.

Other neurology in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →